A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
A Phase 1, Open-label, Single-dose, Pharmacokinetic Study of Mitapivat in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects With Normal Hepatic Function
Sponsor: Agios Pharmaceuticals, Inc.
This PHASE1 trial investigates Moderate Hepatic Impairment and is currently completed. Agios Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Agios Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .